Promomed Group received MA for a powerful broad-spectrum antibiotic

Promomed 14 July 2022

Cefotaxime+Sulbactam has replenished the antibacterial portfolio of the Promomed Group. The advantage of the combination of cephalosporins with sulbactam is the expansion of the antimicrobial spectrum due to effect on gram-negative bacterial strains, which allows the antibiotic to be widely used in medical practice.


The combination of cefotaxime and sulbactam is active against all microorganisms sensitive to cefotaxime. The drug has a broad spectrum. It has been shown to be highly effective in adults and children in the treatment of pneumonia, peritonitis, urinary tract infections, skin and soft tissues infections, and severe forms of infectious and inflammatory diseases.

Responding to the critical challenges of healthcare, the Promomed Group forms a portfolio of drugs for the treatment of socially significant diseases. Developing new drugs, the company offers patients effective and safe drug products thanks to the high quality of their substances, the processibility of production, and the highest quality control standards. The Promomed Group (Biokhimik JSC) produces antibacterial drugs using full-cycle technology.

Cefotaxime+Sulbactam will be available in the form of powder for preparation of solution for intravenous and intramuscular administration at a dosage of 1000 mg +500 mg, which corresponds to standard treatment regimens.

Like most drug products produced by the Promomed Group, this drug is included in the list of vital and essential drugs.